

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that, when receiving a transplant, the incidence of acute graft versus host disease may be higher when a tissue-type matched donor cannot be identified. The chance of finding a matched donor is especially low in people from ethnic minority backgrounds. Therefore, there may be a greater risk of acute graft versus host disease in people from these backgrounds.

Consultees also noted that current treatment for acute graft versus host disease refractory to corticosteroids requires people to regularly travel to specialist centres. The extent and regularity of travel may be more difficult for people with low socioeconomic status.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will take into account relevant equality issues when appraising ruxolitinib.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

Approved by Associate Director (name): Ian Watson

Date: 10/04/2024